CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | Pierre Fabre Pharma Norden AB
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration | Business Wire
Disappointing Nerlynx sales shows Pierre Fabre timing is everything | Evaluate
Puma Biotechnology: Finding Bullish Indications At The End Of 2019 (NASDAQ:PBYI) | Seeking Alpha
Partners of the Pierre Fabre Group: from health to beauty
Blue March: Pierre Fabre supports colorectal cancer awareness month
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
Puma Biotechnology | Evaluate
Partners of the Pierre Fabre Group: from health to beauty
Puma regains China rights to Nerlynx and amends deal with Fabre
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma regains China rights to Nerlynx and amends deal with Fabre
Puma Biotechnology, Pierre Fabre enter into Exclusive License Agreement
Puma and CANBridge cancel licensing deal for $20m
Pierre Fabre amends license agreement with Puma Biotechnology - European Biotechnology
Pierre Fabre engagements | NERLYNX
Fight against cancer : our therapeutic responses | Pierre Fabre
Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe
Puma regains China rights to Nerlynx and amends deal with Fabre
Fight against cancer : our therapeutic responses | Pierre Fabre
